In Brief: Schering/Orion's Fareston
Executive Summary
Schering/Orion's Fareston: "Approvable" as of Jan. 3 for treating advanced breast cancer in postmenopausal women with estrogen receptor-positive tumors or receptor-unknown tumors. The oral anti-estrogen toremifene citrate was unanimously recommended for approval by an FDA advisory committee Oct. 16. Schering-Plough has marketing rights to Fareston in the U.S. through an agreement with Orion-Farmos, the Finnish drug manufacturer that submitted the NDA in December 1994...